5,775 results match your criteria Annals of hematology[Journal]


Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.

Ann Hematol 2019 Apr 19. Epub 2019 Apr 19.

Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Extranodal NK/T cell lymphoma (NKTCL), nasal type (ENKL) that shows no apparent nasal involvement, is termed extranasal NKTCL or non-nasal NKTCL. In this study, we aimed to explore therapeutic approaches and outcomes in patients with extranasal NKTCL in current clinical practice. A data set of patients with newly diagnosed NKTCL who were diagnosed at 31 institutes in Japan between 2000 and 2013 was used for analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03689-9DOI Listing
April 2019
2 Reads

Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkin's lymphoma.

Ann Hematol 2019 Apr 17. Epub 2019 Apr 17.

Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, Bari, Italy.

Thanks to the increased number of young survivors of Hodgkin's lymphoma (HL), management of the pregnancies of women who have a history of exposure to chemotherapies and radiation therapy is becoming increasingly common. Many patients and clinicians are worried that pregnancy after the diagnosis of HL may increase the risk of relapse, despite a lack of empirical evidence to support such concerns. In the present study, we included 89 women diagnosed with HL between 2006 and 2015 under the age of 50 years, who were in complete remission and alive without relapse > 1 year after treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03684-0DOI Listing
April 2019
1 Read

In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.

Ann Hematol 2019 Apr 17. Epub 2019 Apr 17.

Institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Sigmund-Freud str. 25, 53127, Bonn, Germany.

Haemophilia A (HA) is caused by a lack or reduced amount of factor VIII protein (FVIII). About one-third of patients with non-severe HA carrying specific missense mutations show discrepant results between FVIII activity (FVIII:C), measured by one-stage or chromogenic two-stage assays. The aim of this study was to elucidate the mechanism underlying the assay discrepancy in vitro and in silico. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03691-1
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03691-1DOI Listing
April 2019
2 Reads

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.

Ann Hematol 2019 Apr 16. Epub 2019 Apr 16.

Collegium Medicum UMK, University Hospital, Bydgoszcz, Poland.

It has been shown recently that donor and/or recipient cytomegalovirus (CMV) seropositivity is associated with a significant overall survival (OS) decline in acute leukemia patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We now analyzed the prognostic impact of the donor/recipient CMV serostatus in 6968 patients with chronic hematological malignancies who underwent allo-HSCT. Donor and/or recipient CMV seropositivity was associated with a significantly reduced 2-year progression-free survival (PFS, 50% vs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03669-z
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03669-zDOI Listing
April 2019
1 Read

The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.

Ann Hematol 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai, China.

To investigate the effect of chronic graft-versus-host disease (cGVHD) on the outcomes of acute myeloid leukemia (AML) patients who relapsed after allogenic hematopoietic cell transplantation, we performed a retrospective analysis on 218 patients with a median follow-up of 21.4 (3.4-179. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03682-2DOI Listing
April 2019
1 Read

Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.

Ann Hematol 2019 Apr 16. Epub 2019 Apr 16.

Department of Plastic, Reconstructive and Hand Surgery, University Hospital, Regensburg, Germany.

Refractory skin ulcers due to severe chronic graft-versus-host disease (cGVHD) remain to be associated with significant morbidity and mortality.We performed an allogeneic donor skin transplantation in seven adult patients after allogeneic hematopoietic stem cell transplantation for cGVHD-associated refractory skin ulcers. While four patients received a split skin graft (SSG), in one patient, a full thickness skin graft for two small refractory ulcers of the ankle was performed, and one patient received in vitro expanded donor keratinocyte grafts derived from hair roots of the original unrelated donor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03687-xDOI Listing
April 2019
1 Read

Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.

Ann Hematol 2019 Apr 15. Epub 2019 Apr 15.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.

Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-Hodgkin lymphoma for which standard treatment has yet to be established. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a suitable consolidation strategy for patients who respond to induction chemotherapy. The purpose of this study was to compare the outcome and toxicity profile of the combination of busulfan, cyclophosphamide, and etoposide (BuCyE) with that of the combination of thiotepa, busulfan, and cyclophosphamide (TBC) as conditioning regimens of upfront ASCT for consolidation therapy in PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03667-1DOI Listing
April 2019
1 Read

Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.

Ann Hematol 2019 Apr 12. Epub 2019 Apr 12.

Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, 34 Zhongshan North Road, Quanzhou, 362000, Fujian Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03674-2DOI Listing
April 2019
1 Read

Multiple myeloma in elderly patients-a Portuguese multicentric real-life study.

Ann Hematol 2019 Apr 8. Epub 2019 Apr 8.

Hematology Department, Hemato-oncology Unit, Clinical Center of the Champalimaud Center for the Unknown, Av Brasilia, 1400-038, Lisbon, Portugal.

Patients older than 75 years old with multiple myeloma (MM) have shorter survival and are usually treated differently from what features in clinical trials. In this study, the authors characterized the Portuguese population of MM patients above 75 years old, treated between 2009 and 2016. We compared the outcomes obtained with bortezomib-based protocols (BBP), thalidomide-based protocols (TBP), and chemotherapy (CT) using univariate and multivariate controlling for age, performance status, International Staging System score, renal impairment, and number of comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03640-yDOI Listing
April 2019
1 Read

Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles.

Ann Hematol 2019 Apr 7. Epub 2019 Apr 7.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03675-1DOI Listing
April 2019
1 Read

Circulating cell-free DNA for response evaluation of intravascular lymphoma.

Ann Hematol 2019 Apr 6. Epub 2019 Apr 6.

Department of Pathology, Ghent University Hospital, C. Heymanslaan 10, B-9000, Ghent, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03677-zDOI Listing
April 2019
1 Read

Establishing and evaluating an auto-verification system of thalassemia gene detection results.

Ann Hematol 2019 Apr 5. Epub 2019 Apr 5.

The Department of Clinical Laboratory, The First Affiliated Hospital of Shantou University Medical College, Shantou University, Shantou, China.

The manual verification of gene tests is time-consuming and error prone. In this study, we try to explore a high-efficiency, clinically useful auto-verification system for gene detection of thalassemia. A series of verification elements were rooted in the auto-verification system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03656-4DOI Listing
April 2019
1 Read

Increased endothelial activation in α-thalassemia disease.

Ann Hematol 2019 Apr 5. Epub 2019 Apr 5.

Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi District, Bangkok, 10400, Thailand.

One complication of thalassemia is thromboembolism (TE), which is caused by an abnormal red blood cell surface, as well as endothelial and platelet activation. These findings are commonly observed in severe β-thalassemia. However, limited information on α-thalassemia exists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03672-4DOI Listing

Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.

Ann Hematol 2019 Apr 4. Epub 2019 Apr 4.

Department of Hematology, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal.

The identification of high-risk patients deserving alternative first-line treatments to R-CHOP is a research priority in diffuse large B cell lymphoma (DLBCL). Despite the increasing recognition of biological features underlying aggressive behavior, clinical scores remain the basis for prognostic evaluation and treatment stratification in DLBCL. We performed a retrospective analysis of patients with DLBCL uniformly treated with immunochemotherapy with the aim of assessing the discriminative power of the NCCN international prognostic index (IPI) and the GELTAMO-IPI scores in risk group stratification and compared them with the IPI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03676-0DOI Listing
April 2019
2 Reads

Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions.

Ann Hematol 2019 Apr 2. Epub 2019 Apr 2.

Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, A-8036, Graz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03680-4DOI Listing
April 2019
3 Reads

Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies.

Ann Hematol 2019 May 29;98(5):1225-1235. Epub 2019 Mar 29.

Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University of Duesseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

Allogeneic hematopoietic stem cell transplantation (aHSCT) cures a considerable number of patients with myeloid malignancies, but relapse is the most frequent cause of death. We retrospectively studied relapse rate, kinetics, treatment, and outcome after first aHSCT in 446 patients during a 13-year period. Relapse occurred in 167 patients after a median of 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03670-6DOI Listing
May 2019
1 Read

Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results.

Ann Hematol 2019 Mar 28. Epub 2019 Mar 28.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Translocation (11;18)(q21;q21) is found in mucosa-associated lymphoid tissue (MALT) lymphoma, resulting in API2/MALT1 gene fusion. It is known that t(11;18)-positive MALT lymphoma shows a tendency to disseminate and be resistant to Helicobacter pylori eradication by antibiotics. However, the prognostic features including recurrence and histological transformation (HT) remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03671-5DOI Listing
March 2019
2 Reads

Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.

Ann Hematol 2019 Mar 28. Epub 2019 Mar 28.

Institute of Pathology and Neuropathology and Comprehensive Cancer Center, University Hospital Tübingen, Liebermeisterstraße 8, 72076, Tübingen, Germany.

Langerhans cell histiocytosis (LCH) is a clonal histiocytic disorder with recurrent mutations of BRAF and MAP2K1, but data on the impact of genetic features on progression and long-term sequelae are sparse. Cases of pediatric LCH with long-term follow-up from our institution were analyzed for mutations in BRAF and MAP2K1 exons 2 and 3 by immunostaining with mutation-specific VE1 antibody, as well as allele-specific PCR and sequencing, respectively. Clinical and follow-up data were obtained from our files and a questionnaire sent to all former patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03678-yDOI Listing

Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.

Ann Hematol 2019 Mar 27. Epub 2019 Mar 27.

School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski street 25, 40-032, Katowice, Poland.

In the pathway inhibitor era, the number of allogeneic stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) continues to decrease and this approach should be offered only after careful risk-benefit assessment. Nevertheless, ASCT still remains only curative therapeutic modality for CLL, especially in countries with limited access to novel agents. Thirty patients with CLL at median age of 42 years at diagnosis (range 29-64) underwent ASCT between years 2002 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03679-xDOI Listing
March 2019
1 Read

The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study.

Ann Hematol 2019 Mar 27. Epub 2019 Mar 27.

Clinical Center Nursing Department, National Institutes of Health, Bethesda, MD, USA.

The microbiome, an intriguing component of the human body, composed of trillions of microorganisms, has prompted scientific exploration to identify and understand its function and role in health and disease. As associations between microbiome composition, disease, and symptoms accumulate, the future of medicine hinges upon a comprehensive knowledge of these microorganisms for patient care. The oral microbiome may provide valuable and efficient insight for predicting future changes in disease status, infection, or treatment course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03599-wDOI Listing
March 2019
3 Reads

Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.

Ann Hematol 2019 Mar 27. Epub 2019 Mar 27.

Department of Hematology, University Hospitals of Leuven, Herestraat 49, 3000, Leuven, Belgium.

Hydroxyurea (HU) resistance or intolerance occurs in 15 to 24% of patients with polycythemia vera (PV). Resistance to HU is associated with a shortened life expectancy, intolerance has no prognostic value. We assessed the occurrence of HU resistance or intolerance comparing the original (ELNo) versus the modified European Leukemia Net (ELNm) criteria as applied in recent large clinical trials including PV patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03654-6DOI Listing
March 2019
1 Read

Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.

Ann Hematol 2019 Mar 26. Epub 2019 Mar 26.

Division of Hematology, Department of Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.

Post-transplantation cyclophosphamide (PTCy) demonstrated effectiveness to prevent GVHD after haploidentical hematopoietic cell transplantation (HCT). Reducing toxicities with a maximized efficacy is still challenging in HCT. In this retrospective study, we analyzed the safety and efficacy of transplantation from a 1-antigen HLA-mismatched unrelated donor (9/10 MMUD) in 80 patients with hematological disorders between 2010 and 2018; 22 patients received PTCy with a reduced dose of 40 mg/kg, cyclosporine A, and mycophenolate mofetil (MMF); 58 patients received anti-thymocyte globulin (ATG), cyclosporine A, and either methotrexate or MMF for GVHD prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03673-3DOI Listing

Use of eltrombopag in aplastic anemia in Europe.

Ann Hematol 2019 Mar 26. Epub 2019 Mar 26.

Department of Hematology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.

Eltrombopag (ELT), an oral thrombopoietin receptor agonist, has recently emerged as a promising new drug for the treatment of aplastic anemia (AA). How ELT is used outside of clinical trials in the real-world setting and results of this treatment are not known. We conducted therefore a retrospective survey on the use of ELT in AA among EBMT member centers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03652-8DOI Listing
March 2019
1 Read

Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.

Ann Hematol 2019 Mar 26. Epub 2019 Mar 26.

Research Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.

Despite advances in therapy and care for children with acute myeloid leukemia (AML), survival rates for children in low- and middle-income countries (LMICs) remain poor. We studied risk factors for mortality and survival in children with AML in a LMIC to develop strategies to improve survival for AML children in these countries. This retrospective cohort (2000-2014) analyzed newly diagnosed AML patients (age < 19 years) at a reference center in Brazil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03661-7DOI Listing
March 2019
1 Read

Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).

Ann Hematol 2019 Mar 21. Epub 2019 Mar 21.

Department of Medicine A, University Hospital Muenster, Muenster, Germany.

We evaluated pazopanib (800 mg orally QD) in patients not eligible for intensive treatment with relapsed/refractory AML or at initial diagnosis. Patients receiving pazopanib for > 14 days were analyzed for safety, tolerability, and efficacy. Co-primary endpoints were cumulative response rate and reduction of bone marrow microvessel density. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03651-9DOI Listing
March 2019
2 Reads

The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.

Ann Hematol 2019 Mar 21. Epub 2019 Mar 21.

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

This study aimed to explore the clinicopathological features and prognostic correlation of extranodal natural killer (NK)/T cell lymphoma (ENKTCL) in the early stage, screen out the prognostic markers of ENKTCL, and to establish the molecular model of ENKTCL prognosis. A retrospective study was conducted in 88 patients from May 1999 to Dec 2013 in Chinese Academy of Medical Sciences Cancer Hospital, who were diagnosed with ENKTCL according to WHO lymphoid hematopoietic tumor classification (published in 2008). The clinical data and paraffin-embedded tissue blocks were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03643-9DOI Listing

Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.

Ann Hematol 2019 Mar 20. Epub 2019 Mar 20.

Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.

The exact role of regulatory T cells (Tregs) in multiple myeloma (MM) has not been yet determined. Data regarding alterations of Tregs during therapy with novel agents (NA), i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03657-3DOI Listing
March 2019
1 Read

Prevalence of extramedullary hematopoiesis, renal cysts, splenic and hepatic lesions, and vertebral hemangiomas among thalassemic patients: a retrospective study from the Myocardial Iron Overload in Thalassemia (MIOT) network.

Ann Hematol 2019 Mar 20. Epub 2019 Mar 20.

Magnetic Resonance Imaging Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy.

We determined the prevalence of incidental extracardiac findings (IEF) at Magnetic Resonance Imaging (MRI) potentially related to anemia and hypoxia in age- and sex-matched populations (N = 318) with thalassemia major (TM) and thalassemia intermedia (TI) enrolled in the Myocardial Iron Overload in Thalassemia network. Overall, IEFs were detected in 33.3% and 25. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03659-1DOI Listing

Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.

Ann Hematol 2019 Mar 20. Epub 2019 Mar 20.

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Rd, Xuzhou, 221002, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03658-2DOI Listing
March 2019
1 Read

Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma.

Ann Hematol 2019 Mar 16. Epub 2019 Mar 16.

Institute of Haematology and Centre of Haemato-Oncology Research (CREO), University and Hospital of Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03664-4DOI Listing
March 2019
1 Read

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma.

Ann Hematol 2019 Mar 16. Epub 2019 Mar 16.

Hematology Service, University Hospital Doctor Peset, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03663-5DOI Listing
March 2019
2 Reads

Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia.

Ann Hematol 2019 Mar 15. Epub 2019 Mar 15.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03666-2DOI Listing

Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.

Ann Hematol 2019 Mar 15. Epub 2019 Mar 15.

Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 17 Agiou Thoma street, 11527, Athens, Greece.

Poly (ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme that participates in the DNA repair of malignant cells, with various consequences on their survival. We have recently shown that PARP1 mRNA levels in the bone marrow of patients with myelodysplastic syndrome (MDS) are correlated to prognosis. To evaluate PARP1 as a biomarker of response to 5-azacytidine in patients with MDS, we measured PARP1 mRNA levels by a quantitative real-time PCR in diagnostic bone marrow samples of 77 patients with MDS treated with 5-azacytidine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03650-wDOI Listing
March 2019
2 Reads

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.

Ann Hematol 2019 Mar 14. Epub 2019 Mar 14.

Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.

Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination. The median of prior lines of therapy was 3 and all patients were previously exposed to proteasome inhibitors and lenalidomide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03649-3DOI Listing

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

Ann Hematol 2019 Mar 14. Epub 2019 Mar 14.

Service d'hématologie Clinique, Centre Hospitalier Universitaire, Nantes, France.

The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMID), or who are double refractory to a PI and an IMID. To date, no real-life data on the efficacy and tolerance of daratumumab in this setting are available. We report here the results of a single-center series of 41 RRMM patients treated with single-agent daratumumab outside clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03655-5DOI Listing
March 2019
3 Reads

Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.

Ann Hematol 2019 Mar 14. Epub 2019 Mar 14.

Haematology, "Policlinico" Hospital, Bari, Italy.

This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)-pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin's lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03662-6DOI Listing
March 2019
1 Read

Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study.

Ann Hematol 2019 May 13;98(5):1083-1093. Epub 2019 Mar 13.

CEINGE Biotecnologie Avanzate, Naples, Italy.

In this study, we aimed at disclosing the main features of paroxysmal nocturnal hemoglobinuria (PNH) clones, their association with presentation syndromes, and their changes during follow-up. A large-scale, cooperative collection (583 clones from 529 patients) of flow cytometric and clinical data was entered into a national repository. Reason for testing guidelines were provided to the 41 participating laboratories, which followed the 2010 technical recommendations for PNH testing by Borowitz. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03644-8DOI Listing
May 2019
3 Reads

Isolated extramedullary leukemic involvement of the heart presenting as fulminant heart failure.

Ann Hematol 2019 Mar 11. Epub 2019 Mar 11.

Second Department of Internal Medicine, ATTIKO General University Hospital, National and Kapodistrian University of Athens, Rimini-1, Haidari, 124 62, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03665-3DOI Listing
March 2019
1 Read

Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukemia.

Ann Hematol 2019 Mar 11. Epub 2019 Mar 11.

Department of Hematopathology, Medanta - The Medicity, Sector 38, Gurgaon, 122001, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03660-8DOI Listing

Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome.

Ann Hematol 2019 Mar 11. Epub 2019 Mar 11.

Department of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Japan.

We conducted a nationwide retrospective study to evaluate the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 651 patients aged 60-69 years with de novo myelodysplastic syndrome (MDS). We divided patients into two groups: 152 and 499 patients with an early and advanced disease status, respectively. The 3-year overall survival (OS) rate of patients with an early disease status was 45. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03653-7DOI Listing
March 2019
2 Reads

Thromboembolic events in polycythemia vera.

Ann Hematol 2019 May 8;98(5):1071-1082. Epub 2019 Mar 8.

Hospital del Mar-IMIM, Passeig Marítim 25-29, 08003, Barcelona, Spain.

Thromboembolic events and cardiovascular disease are the most prevalent complications in patients with polycythemia vera (PV) compared with other myeloproliferative disorders and are the major cause of morbidity and mortality in this population. Moreover, a vascular complication such as arterial or venous thrombosis often leads to the diagnosis of PV. The highest rates of thrombosis typically occur shortly before or at diagnosis and decrease over time, probably due to the effects of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03625-xDOI Listing
May 2019
5 Reads

Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome.

Ann Hematol 2019 Mar 5. Epub 2019 Mar 5.

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 80 Vasilissis Sofias, 11258, Athens, Greece.

Pre-existing pulmonary disease may affect treatment choices, toxicity, and survival of patients with multiple myeloma (MM). However, data on the prognostic value of pulmonary function tests (PFTs) in myeloma patients' outcome, at the time of initial assessment of newly diagnosed patients, are scarce. Here, we prospectively performed PFTs in 121 newly diagnosed MM patients, before initiation of treatment, and we evaluated possible associations of lung function with their outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03641-xDOI Listing
March 2019
10 Reads

Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus.

Ann Hematol 2019 Mar 4. Epub 2019 Mar 4.

Department of Hematology, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xicheng District, Beijing, 100050, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03647-5DOI Listing
March 2019
3 Reads

Successful management of transcatheter aortic valve implantation by platelet transfusions in a nonagenarian patient with severe autoimmune factor V deficiency.

Ann Hematol 2019 Mar 4. Epub 2019 Mar 4.

Centre de Référence des Pathologies Plaquettaires Constitutionnelles, Hôpital cardiologique, Centre Hospitalo-Universitaire de Bordeaux, Pessac, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03646-6DOI Listing
March 2019
1 Read

A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots.

Ann Hematol 2019 Mar 4. Epub 2019 Mar 4.

Department of Laboratory Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, H-4032, Hungary.

Acute promyelocytic leukemia (APL) is generally characterized by t(15;17)(q24;q21). In some cases, the classic translocation cannot be identified by conventional methods, since the PML-RARA fusion protein results from complex, variant, or cryptic translocation. The diagnostic algorithm of APL starts with screening methods, such as flow cytometry (FC), followed by fluorescence in situ hybridization or polymerase chain reaction to confirm the diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03642-wDOI Listing
March 2019
1 Read

Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma.

Ann Hematol 2019 Mar 1. Epub 2019 Mar 1.

Department Hematology and Rheumatology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03645-7DOI Listing
March 2019
2 Reads

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

Ann Hematol 2019 May 1;98(5):1217-1224. Epub 2019 Mar 1.

Global Clinical Research, Mylan, 1000 Mylan Boulevard, Canonsburg, PA, 15317, USA.

Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as prophylaxis for chemotherapy-induced neutropenia. This was a phase 3, multicenter, randomized, double-blind, parallel-group equivalence trial of MYL-1401H vs European Union-sourced reference pegfilgrastim. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03639-5DOI Listing
May 2019
4 Reads
2.634 Impact Factor

Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.

Ann Hematol 2019 May 1;98(5):1209-1216. Epub 2019 Mar 1.

Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka City, Iwate, 020-8505, Japan.

Febrile neutropenia is often observed in patients with hematologic malignancies, especially in those with acute leukemia. Meropenem has potent and broad antibacterial activity against gram-positive and gram-negative bacteria, and is recommended as first-line empiric therapy for febrile neutropenia. In contrast, the safety and efficacy of doripenem in patients with febrile neutropenia and hematologic malignancies is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03634-wDOI Listing
May 2019
2 Reads

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.

Ann Hematol 2019 May 23;98(5):1159-1168. Epub 2019 Feb 23.

INSERM U1218, University of Bordeaux, 146 rue Léo Saignat CS 61292, 33076, Bordeaux Cedex, France.

Early molecular response has been associated with clinical outcome in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors. The BCR-ABL1 transcript rate decline from baseline to 3 months has been demonstrated to be more predictive than a single BCR-ABL1 level at 3 months (M3). However, it cannot be used routinely because ABL1, as an internal gene control, is not reliable for BCR-ABL1 quantification above 10%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03633-xDOI Listing
May 2019
1 Read